Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients With Glioblastoma (GBM)

NCT02336165 is registered in ClinicalTrials.gov with Ludwig Institute for Cancer Research as lead sponsor.

NCT NCT02336165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02336165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients With Glioblastoma (GBM)
Lead sponsor
Ludwig Institute for Cancer Research
Phase
Phase 2
Overall status
Completed
Start date
February 26, 2015
Completion date
July 6, 2021
Enrollment
159 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma